We came across a bullish thesis on Nurix Therapeutics, Inc. on Clinical Catalysts’s Substack. In this article, we will summarize the bulls’ thesis on NRIX. Nurix Therapeutics, Inc.'s share was trading at $17.59 as of January 29th.
[caption id="attachment_522188" align="aligncenter" width="750"]Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and...
Create a free account, or log in to read the full article
No credit card required.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.